{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:43:44Z","timestamp":1792133024205,"version":"4.4.0"},"reference-count":83,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T00:00:00Z","timestamp":1634601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Endometrial cancer (EC) is currently the most common malignancy of the female genital tract in developed countries. Although it is more common in postmenopausal women, it may affect up to 25% in the premenopausal age and 3\u20135% under the age of 40 years. Furthermore, in the last decades a significant shift to pregnancy at older maternal ages, particularly in resource-rich countries, has been observed. Therefore, in this scenario fertility-sparing alternatives should be discussed with patients affected by EC. This study summarizes available literature on fertility-sparing management of patients affected by EC, focusing on the oncologic and reproductive outcomes. A systematic computerized search of the literature was performed in two electronic databases (PubMed and MEDLINE) in order to identify relevant articles to be included for the purpose of this systematic review. On the basis of available evidence, fertility-sparing alternatives are oral progestins alone or in combination with other drugs, levonorgestrel intrauterine system and hysteroscopic resection in association with progestin therapies. These strategies seem feasible and safe for young patients with G1 endometrioid EC limited to the endometrium. However, there is a lack of high-quality evidence on the efficacy and safety of fertility-sparing treatments and future well-designed studies are required.<\/jats:p>","DOI":"10.3390\/jcm10204784","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T03:01:13Z","timestamp":1634698873000},"page":"4784","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Fertility-Sparing Treatment of Patients with Endometrial Cancer: A Review of the Literature"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3744-2668","authenticated-orcid":false,"given":"Umberto","family":"Leone Roberti Maggiore","sequence":"first","affiliation":[{"name":"Gynecologic Oncology, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rola","family":"Khamisy-Farah","sequence":"additional","affiliation":[{"name":"Clalit Health Service, Akko, Azrieli Faculty of Medicine, Bar-Ilan University, Safed 13100, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8409-868X","authenticated-orcid":false,"given":"Nicola Luigi","family":"Bragazzi","sequence":"additional","affiliation":[{"name":"Laboratory for Industrial and Applied Mathematics (LIAM), Department of Mathematics and Statistics, York University, Toronto, ON M3J 1P3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8373-8569","authenticated-orcid":false,"given":"Giorgio","family":"Bogani","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4863-1747","authenticated-orcid":false,"given":"Fabio","family":"Martinelli","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Lopez","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Chiappa","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Signorelli","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Ditto","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Raspagliesi","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ygyno.2009.08.011","article-title":"A review of the challenges faced in the conservative treatment of young women with endometrial carcinoma and risk of ovarian cancer","volume":"115","author":"Zivanovic","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJM199608293350907","article-title":"Endometrial carcinoma","volume":"335","author":"Rose","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/IGC.0000000000000609","article-title":"ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up","volume":"26","author":"Colombo","year":"2016","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ygyno.2010.12.343","article-title":"Advances in the management of endometrial carcinoma","volume":"120","author":"Leitao","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/1097-0142(19901015)60:8+<2035::AID-CNCR2820601515>3.0.CO;2-8","article-title":"Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study","volume":"60","author":"Creasman","year":"1987","journal-title":"Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ygyno.2015.09.020","article-title":"The impact of BMI on surgical complications and outcomes in endometrial cancer surgery\u2014An institutional study and systematic review of the literature","volume":"139","author":"Bouwman","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ygyno.2017.01.025","article-title":"Impact of body mass index and operative approach on surgical morbidity and costs in women with endometrial carcinoma and hyperplasia","volume":"145","author":"Suidan","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jmig.2017.07.022","article-title":"Updates on Conservative Management of Endometrial Cancer","volume":"25","author":"Corzo","year":"2018","journal-title":"J. Minim Invasive Gynecol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.fertnstert.2013.11.028","article-title":"Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: Systematic review and meta-analysis","volume":"101","author":"Koskas","year":"2014","journal-title":"Fertil. Steril."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ygyno.2014.02.020","article-title":"Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin","volume":"133","author":"Simpson","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ygyno.2020.11.007","article-title":"Continued medical treatment for persistent early endometrial cancer in young women","volume":"160","author":"Cho","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.23736\/S0026-4806.20.07072-X","article-title":"Fertility-sparing management for endometrial cancer: Review of literature","volume":"112","author":"Garzon","year":"2021","journal-title":"Minerva Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"57642","DOI":"10.18632\/oncotarget.17588","article-title":"Comparison among fertility-sparing therapies for well differentiated early-stage endometrial carcinoma and complex atypical hyperplasia","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/IGC.0b013e31819c5372","article-title":"Efficacy of megestrol acetate (megace) in the treatment of patients with early endometrial adenocarcinoma: Our experiences with 21 patients","volume":"19","author":"Eftekhar","year":"2009","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1200\/JCO.2006.08.8344","article-title":"Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women","volume":"25","author":"Ushijima","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1471-0528.2008.02024.x","article-title":"Fertility-sparing treatment in young women with endometrial cancer or atypical complex hyperplasia: A prospective single-institution experience of 21 cases","volume":"116","author":"Signorelli","year":"2009","journal-title":"BJOG"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"358.e1","DOI":"10.1016\/j.ajog.2013.06.031","article-title":"Combined medroxyprogesterone acetate\/levonorgestrel-intrauterine system treatment in young women with early-stage endometrial cancer","volume":"209","author":"Kim","year":"2013","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.3802\/jgo.2019.30.e57","article-title":"Efficacy and fertility outcomes of levonorgestrel-releasing intra-uterine system treatment for patients with atypical complex hyperplasia or endometrial cancer: A retrospective study","volume":"30","author":"Martinelli","year":"2019","journal-title":"J. Gynecol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1097\/IGC.0000000000000467","article-title":"Fertility-Sparing Treatment of Early Endometrial Cancer and Complex Atypical Hyperplasia in Young Women of Childbearing Potential","volume":"25","author":"Pronin","year":"2015","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/IGC.0000000000001164","article-title":"Fertility-Preserving Treatment in Young Women With Grade 1 Presumed Stage IA Endometrial Adenocarcinoma: A Meta-Analysis","volume":"28","author":"Fan","year":"2018","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ygyno.2020.02.008","article-title":"The addition of metformin to progestin therapy in the fertility-sparing treatment of women with atypical hyperplasia\/endometrial intraepithelial neoplasia or endometrial cancer: Little impact on response and low live-birth rates","volume":"157","author":"Murdock","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/annonc\/mdv539","article-title":"Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer","volume":"27","author":"Mitsuhashi","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/1471-0528.16108","article-title":"Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: A randomised controlled trial","volume":"127","author":"Yang","year":"2020","journal-title":"BJOG"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.3802\/jgo.2019.30.e90","article-title":"Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients","volume":"30","author":"Mitsuhashi","year":"2019","journal-title":"J. Gynecol. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ygyno.2019.01.014","article-title":"Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer","volume":"153","author":"Yang","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.3802\/jgo.2017.28.e2","article-title":"Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer","volume":"28","author":"Falcone","year":"2017","journal-title":"J. Gynecol. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.ejca.2012.09.017","article-title":"Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002)","volume":"49","author":"Park","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1097\/IGC.0000000000000098","article-title":"Fertility-preserving treatment in young women with endometrial adenocarcinoma: A long-term cohort study","volume":"24","author":"Wang","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ijgo.2012.06.010","article-title":"A Turkish Gynecologic Oncology Group study of fertility-sparing treatment for early-stage endometrial cancer","volume":"119","author":"Dursun","year":"2012","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/ijgc-2018-000036","article-title":"Pregnancy and oncologic outcomes after fertility-sparing management for early stage endometrioid endometrial cancer","volume":"29","author":"Chae","year":"2019","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.fertnstert.2008.12.009","article-title":"Conservative surgical management of stage IA endometrial carcinoma for fertility preservation","volume":"93","author":"Mazzon","year":"2010","journal-title":"Fertil. Steril."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1097\/IGC.0000000000000825","article-title":"Long-Term Oncologic and Reproductive Outcomes in Young Women With Early Endometrial Cancer Conservatively Treated: A Prospective Study and Literature Update","volume":"26","author":"Laurelli","year":"2016","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/IGC.0b013e3181aae1fb","article-title":"Conservative treatment with progestin and pregnancy outcomes in endometrial cancer","volume":"19","author":"Hahn","year":"2009","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00404-014-3417-z","article-title":"Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: Our experience and a review of the literature","volume":"291","author":"Sawada","year":"2015","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/AOG.0b013e3182964ce3","article-title":"Hormonal therapy for women with stage IA endometrial cancer of all grades","volume":"122","author":"Park","year":"2013","journal-title":"Obstet. Gynecol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00404-011-2021-8","article-title":"Pregnancy outcome in patients with stage 1a endometrial adenocarcinoma, who conservatively treated with megestrol acetate","volume":"285","author":"Shirali","year":"2012","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00404-011-1959-x","article-title":"Effectiveness of high-dose progestin and long-term outcomes in young women with early-stage, well-differentiated endometrioid adenocarcinoma of uterine endometrium","volume":"285","author":"Park","year":"2012","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/IGC.0b013e31820003de","article-title":"Prolonged conservative treatment of endometrial cancer patients: More than 1 pregnancy can be achieved","volume":"21","author":"Perri","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"255.e1","DOI":"10.1016\/j.ajog.2013.11.001","article-title":"Reproductive and oncologic outcomes after progestin therapy for endometrial complex atypical hyperplasia or carcinoma","volume":"210","author":"Kudesia","year":"2014","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1080\/14656566.2018.1462337","article-title":"Levonorgestrel-releasing intra-uterine systems as female contraceptives","volume":"19","author":"Grandi","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1067\/mob.2002.122130","article-title":"Intrauterine progesterone treatment of early endometrial cancer","volume":"186","author":"Montz","year":"2002","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.ygyno.2004.09.010","article-title":"Levonorgestrel-releasing intrauterine system (LNG-IUS) as a therapy for endometrial carcinoma","volume":"95","author":"Giannopoulos","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.ygyno.2004.10.031","article-title":"Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature","volume":"97","author":"Dhar","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/AOG.0000000000002390","article-title":"Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device","volume":"131","author":"Pal","year":"2018","journal-title":"Obstet. Gynecol."},{"key":"ref_47","first-page":"673","article-title":"Conservative treatment with medroxyprogesterone acetate plus levonorgestrel intrauterine system for early-stage endometrial cancer in young women: Pilot study","volume":"21","author":"Kim","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/jjco\/hys171","article-title":"Treatment with medroxyprogesterone acetate plus levonorgestrel-releasing intrauterine system for early-stage endometrial cancer in young women: Single-arm, prospective multicenter study: Korean gynecologic oncology group study (KGOG2009)","volume":"42","author":"Kim","year":"2012","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.3802\/jgo.2019.30.e47","article-title":"Six months response rate of combined oral medroxyprogesterone\/levonorgestrel-intrauterine system for early-stage endometrial cancer in young women: A Korean Gynecologic-Oncology Group Study","volume":"30","author":"Kim","year":"2019","journal-title":"J. Gynecol. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ygyno.2009.09.024","article-title":"Metformin is a potent inhibitor of endometrial cancer cell proliferation\u2014Implications for a novel treatment strategy","volume":"116","author":"Cantrell","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jsbmb.2010.12.006","article-title":"Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells","volume":"126","author":"Xie","year":"2011","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1210\/jc.2010-1803","article-title":"Metformin treatment exerts antiinvasive and antimetastatic effects in human endometrial carcinoma cells","volume":"96","author":"Tan","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/IGC.0b013e318207dac7","article-title":"Metformin reverses progestin resistance in endometrial cancer cells by downregulating GloI expression","volume":"21","author":"Zhang","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e035416","DOI":"10.1136\/bmjopen-2019-035416","article-title":"Medroxyprogesterone acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and endometrial carcinoma: Trial protocol for a prospective, randomised, open, blinded-endpoint design, dose-response trial (FELICIA trial)","volume":"10","author":"Mitsuhashi","year":"2020","journal-title":"BMJ Open"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ygyno.2010.10.004","article-title":"Conservative treatment of early endometrial cancer: Preliminary results of a pilot study","volume":"120","author":"Laurelli","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/ijgo.13253","article-title":"Long-term survival of young endometrial cancer patients desiring fertility preservation treated with hysteroscopic resection followed by hormone therapy (NEMO technique)","volume":"151","author":"Mazzon","year":"2020","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"ref_57","first-page":"1","article-title":"First births to older women continue to rise","volume":"152","author":"Matthews","year":"2014","journal-title":"NCHS Data Brief"},{"key":"ref_58","first-page":"1","article-title":"Births: Final Data for 2014","volume":"64","author":"Hamilton","year":"2015","journal-title":"Natl. Vital Stat. Rep."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jmig.2020.12.027","article-title":"Fertility-sparing Surgery for Patients with Cervical, Endometrial, and Ovarian Cancers","volume":"28","author":"Kohn","year":"2021","journal-title":"J. Minim. Invasive Gynecol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1749-6632.2001.tb03811.x","article-title":"Role of exogenous and endogenous hormones in endometrial cancer: Review of the evidence and research perspectives","volume":"943","author":"Akhmedkhanov","year":"2001","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/0026-0495(65)90024-7","article-title":"Histological Effects of Progestins on Hyperplasia and Carcinoma in Situ of the Endometrium\u2014Further Observations","volume":"14","author":"Steiner","year":"1963","journal-title":"Metabolism"},{"key":"ref_62","first-page":"235","article-title":"Treatment of endometrial carcinoma with a progestogen. Report of a case","volume":"62","author":"Liggins","year":"1963","journal-title":"N. Z. Med. J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/00006250-196409000-00007","article-title":"Effect of a Progestational Agent on Endometrial Hyperplasia and Endometrial Cancer","volume":"24","author":"Wentz","year":"1964","journal-title":"Obstet. Gynecol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/1097-0142(195911\/12)12:6<1106::AID-CNCR2820120607>3.0.CO;2-M","article-title":"Histological effects of progestins on hyperplasia and carcinoma in situ of the endometrium","volume":"12","author":"Kistner","year":"1959","journal-title":"Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/1097-0142(19850715)56:2<403::AID-CNCR2820560233>3.0.CO;2-X","article-title":"The behavior of endometrial hyperplasia. A long-term study of \u2018untreated\u2019 hyperplasia in 170 patients","volume":"56","author":"Kurman","year":"1985","journal-title":"Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ajog.2015.03.037","article-title":"Levonorgestrel-releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia: A systematic review and metaanalysis of randomized trials","volume":"213","author":"Ghayaty","year":"2015","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ygyno.2011.11.043","article-title":"Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: A meta-analysis and systematic review of the literature","volume":"125","author":"Baker","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_68","unstructured":"Biology Education Practical Standards Committee EFoSfUiM (2006). Minimum training recommendations for the practice of medical ultrasound. Ultraschall Med., 27, 79\u2013105."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.3802\/jgo.2020.31.e74","article-title":"Fertility-sparing treatment for intramucous, moderately differentiated, endometrioid endometrial cancer: A Gynecologic Cancer Inter-Group (GCIG) study","volume":"31","author":"Falcone","year":"2020","journal-title":"J. Gynecol. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1634\/theoncologist.2017-0285","article-title":"Fertility-Sparing Treatment of Endometrial Cancer with Initial Infiltration of Myometrium by Resectoscopic Surgery: A Pilot Study","volume":"23","author":"Casadio","year":"2018","journal-title":"Oncologist"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Casadio, P., La Rosa, M., Alletto, A., Magnarelli, G., Arena, A., Fontana, E., Fabbri, M., Giovannico, K., Virgilio, A., and Raimondo, D. (2020). Fertility Sparing Treatment of Endometrial Cancer with and without Initial Infiltration of Myometrium: A Single Center Experience. Cancers, 12.","DOI":"10.3390\/cancers12123571"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network, Kandoth, C., Schultz, N., Cherniack, A.D., Akbani, R., Liu, Y., Shen, H., Robertson, A.G., Pashtan, I., and Shen, R. (2013). Integrated genomic characterization of endometrial carcinoma. Nature, 497, 67\u201373.","DOI":"10.1038\/nature12113"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"370.e1","DOI":"10.1016\/j.ajog.2020.10.003","article-title":"Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer","volume":"224","author":"Chung","year":"2021","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3892\/mco.2016.748","article-title":"Measurement of endometrial thickness by transvaginal ultrasonography to predict pathological response to medroxyprogesterone acetate in patients with grade 1 endometrioid adenocarcinoma","volume":"4","author":"Sato","year":"2016","journal-title":"Mol. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ygyno.2011.11.004","article-title":"Predictors of resolution of complex atypical hyperplasia or grade 1 endometrial adenocarcinoma in premenopausal women treated with progestin therapy","volume":"124","author":"Penner","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ejogrb.2018.10.025","article-title":"PTEN as a predictive marker of response to conservative treatment in endometrial hyperplasia and early endometrial cancer. A systematic review and meta-analysis","volume":"231","author":"Travaglino","year":"2018","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/aogs.13586","article-title":"Should progesterone and estrogen receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis","volume":"98","author":"Raffone","year":"2019","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.jmig.2020.10.009","article-title":"Predictive Accuracy of Progesterone Receptor B in Young Women with Atypical Endometrial Hyperplasia and Early Endometrial Cancer Treated with Hysteroscopic Resection plus LNG-IUD Insertion","volume":"28","author":"Raffone","year":"2021","journal-title":"J. Minim. Invasive Gynecol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"237","DOI":"10.5653\/cerm.2020.03629","article-title":"Fertility-sparing treatment in women with endometrial cancer","volume":"47","author":"Won","year":"2020","journal-title":"Clin. Exp. Reprod. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12958-021-00808-y","article-title":"Analysis of pregnancy-associated factors after fertility-sparing therapy in young women with early stage endometrial cancer or atypical endometrial hyperplasia","volume":"19","author":"Fan","year":"2021","journal-title":"Reprod. Biol. Endocrinol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.3802\/jgo.2018.29.e21","article-title":"Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility?","volume":"29","author":"Yamagami","year":"2018","journal-title":"J. Gynecol. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/jog.13473","article-title":"Efficacy of medroxyprogesterone acetate treatment and retreatment for atypical endometrial hyperplasia and endometrial cancer","volume":"44","author":"Tamauchi","year":"2018","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ygyno.2012.12.037","article-title":"Progestin re-treatment in patients with recurrent endometrial adenocarcinoma after successful fertility-sparing management using progestin","volume":"129","author":"Park","year":"2013","journal-title":"Gynecol. Oncol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/20\/4784\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:17:46Z","timestamp":1760167066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/20\/4784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,19]]},"references-count":83,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["jcm10204784"],"URL":"https:\/\/doi.org\/10.3390\/jcm10204784","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,19]]}}}